Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stimulation of Regional Lipolysis and Adipocyte Lipolysis Proteins
NCT06416969Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2024
- Primary completion
- Jan 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of somatostatin and epinephrine in obesity (2 arms), sponsored by Mayo Clinic. Primary endpoints: Free Fatty Acid release from femoral, splanchnic and upper body subcutaneous adipose tissue at 3.5 hours and Stimulated FFA release in volunteers with and without obesity at 3.5 hours. Started Jan 2024; status: recruiting.
02
Drugs
somatostatinepinephrine
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06416969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416969.